OBJ 0.00% 1.5¢ obj limited

forget trader noise and look at the big scene

  1. 3,891 Posts.
    Thursday, 1 October 2009
    US STUDY RESULTS
    OBJ Limited (ASX: OBJ) advises that it has now received the final report from Azopharma
    covering the Company’s research collaboration with a global Fast Moving Consumer Goods
    (FMCG) company. The report by Azopharma Contract Services Inc, a GLP/GMP accredited
    contract research organisation in Miami Florida, sets out the results of an eight-month patch
    development and evaluation program. The study tested the delivery performance of OBJ’s
    Dermaportation and ETP technologies in a fully formulated patch format, when compared to
    an existing Over the Counter (OTC) drug product with significant international sales.
    In 2008, OBJ advised the market that it had entered into an Agreement with a major
    international FMCG company to evaluate OBJ’s two main technologies and had engaged
    Azopharma Contract Services Inc as the independent Contract Research Organisation (CRO) to
    undertake the formulation and evaluation phases.
    The FMCG company’s stated objective in the Agreement with OBJ was to achieve up to a 10-
    fold increase in drug delivery over an existing commercial product. Under the terms of the
    Agreement, OBJ is restricted from disclosing any information relating to the drug tested, the
    comparative product or the market. However the following graph by Azopharma illustrates
    the relative performance and the achievement of the FMCG’s objectives.

    Sorry but couldnt paste, but suffice to say the graph tells a big story...


    The Azopharma Report, which remains the property of the FMCG company, stated in
    the Executive Summary that:
    “The developed patch system effectively fluxes
    approximately a 10-fold over the existing product
    comparatively”
    “The development work to this point justifies proof-ofconcept
    of the formulation and technology to proceed
    further into the pharmaceutical development of a drug
    product.”

    OBJ is very pleased to have independent validation by an internationally accredited
    laboratory. It provides confidence and lays the foundations for potential commercial
    development in pharmaceutical and cosmetic applications.
    These test results are significant to the Company to the extent that attention to
    development of selected patch products with suitable international partners can now
    become more focused. It is the intention of OBJ to expedite securing commercial
    partners to embrace the use of OBJ’s patch technologies into the most appropriate
    applications.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.